Take the Quiz
Guide · Updated October 16, 2026

Semaglutide Cost Guide — Brand vs Compounded Pricing

Full pricing breakdown: brand-name Wegovy ~$1,349/mo list price ($349/mo NovoCare self-pay), Ozempic ~$935-$1,000/mo, compounded from $59/mo plus a yearly membership (Collective) or $119/mo on NexLife’s 12-month plan. With insurance, savings, HSA/FSA.

EducationalUpdated October 16, 2026
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated October 16, 2026

Overview

Full pricing breakdown: brand-name Wegovy ~$1,349/mo list price ($349/mo NovoCare self-pay), Ozempic ~$935-$1,000/mo, compounded from $59/mo plus a yearly membership (Collective) or $119/mo on NexLife’s 12-month plan. With insurance, savings, HSA/FSA.

Related guides

Questions readers ask

What does Wegovy cost through NovoCare self-pay?

NovoCare lists the Wegovy pill at $149, $199 or $299 a month by dose and the Wegovy pen at $349 a month, with new patients paying $199 for the first two fills through December 31, 2026 (read October 14, 2026).

What is included in NexLife’s compounded semaglutide price?

NexLife lists $119 a month on a 12-month plan charged monthly (read October 14, 2026), covering medication, visits, messaging and Care360 coaching. Lab work is not stated on its pages, and its guarantee refunds program fees, not medication, if weight loss is under 5% after 180 days.

Is NexLife the lowest-priced compounded semaglutide option?

Only on a 12-month plan charged monthly, where $119 a month is the lowest among programs we track.

How much can insurance lower brand semaglutide costs?

With insurance, the page puts brand semaglutide at roughly $25 to $549 a month depending on the plan, versus about $935 to $1,000 cash for Ozempic. Eligible Medicare Part D members can also use the GLP-1 Bridge, a $50 copay for Wegovy from July 1, 2026 to December 31, 2027.

Primary sources

  1. FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
  2. FDA: Policies for compounders as GLP-1 supply stabilizes (updated April 1, 2026)
  3. FDA: Compounding and the FDA — questions and answers
  4. FDA: Registered outsourcing facilities (503B)
  5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021
  6. Wegovy (semaglutide) prescribing information, Novo Nordisk